Product How it works Pricing Blog FAQ About Contact
BioCryst Pharmaceuticals

BioCryst Pharmaceuticals (NASDAQ: BCRX) revenue

BioCryst Pharmaceuticals reported revenue of $874.8m for fiscal 2025, 94.1% more than in fiscal 2024 ($450.7m). Since fiscal 2016 its revenue has grown by 3,219.7%, an average growth of 47.6% a year.

BioCryst Pharmaceuticals has grown its revenue for 5 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. The biggest drop was in fiscal 2020, −63.5%.

Revenue, in millions of US dollars26.4201625.2201720.7201848.8201917.82020157.22021270.82022331.42023450.72024874.82025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$874.8m+94.1%$341.0m39.0%
2024$450.7m+36.0%−$2.5m−0.6%
2023$331.4m+22.4%−$103.7m−31.3%
2022$270.8m+72.3%−$148.4m−54.8%
2021$157.2m+782.4%−$177.7m−113.1%
2020$17.8m−63.5%−$174.8m−981.1%
2019$48.8m+136.5%−$99.5m−203.7%
2018$20.7m−18.0%−$94.2m−456.2%
2017$25.2m−4.4%−$57.4m−227.9%
2016$26.4m—−$48.6m−184.4%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

BioCryst Pharmaceuticals revenue compared with its sector

By revenue for its latest fiscal year, BioCryst Pharmaceuticals ranks 159th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; BioCryst Pharmaceuticals, 94.1%.

RankCompanyRevenueRevenue growth
157thANI Pharmaceuticals$883.4m43.8%
158thNutex Health$875.3m82.4%
159thBioCryst Pharmaceuticals$874.8m94.1%
160thWarby Parker$871.9m13.0%
161stNeogen$870.4m−2.7%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of BioCryst Pharmaceuticals

How much revenue did BioCryst Pharmaceuticals make in fiscal 2025?
BioCryst Pharmaceuticals reported revenue of $874.8m for fiscal 2025, compared with $450.7m in fiscal 2024.
How much has the revenue of BioCryst Pharmaceuticals grown?
Between fiscal 2016 and fiscal 2025 it went from $26.4m to $874.8m: 3,219.7% more, an average growth of 47.6% a year.
What was the best year for revenue at BioCryst Pharmaceuticals?
Of its last 10 fiscal years, fiscal 2025, with $874.8m.
Where does BioCryst Pharmaceuticals rank in its sector by revenue?
It ranks 159th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for BioCryst Pharmaceuticals come from?
From the annual report (Form 10-K) that BioCryst Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that BioCryst Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on BioCryst Pharmaceuticals: the BioCryst Pharmaceuticals page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.